Office-Based Opioid Treatment Resources
With an emphasis on medication assistance and coordinating integrated outpatient care services in treatment of patients with opioid dependence, office-based opioid treatment (OBOT) programs have proven to be effective, confidential, accessible and safe. They have resulted in overall reduced substance use in patients as well as in overall retention in treatment, recovery, and integration in the mainstream. The use of buprenorphine in treating opioid dependence (especially with a medication assisted model) is supported by medical literature, such as the evidenced-based retention percentages documented by the 2003 Kakko study as well as others at Yale, Hopkins and NIDA.
To work toward supporting best practices in OBOT care, Magellan convened a panel of physicians who have successfully used OBOT over time. Panel members outlined the specific barriers to providing OBOT services, along with practical solutions. These collective suggestions comprise Magellan’s OBOT Provider Resource Kit, which covers topics such as overcoming logistical issues, managing the number of OBOT patients, and how we can help you provide services.
Robert Ciaverelli, M.D., vice president of medical services, Magellan’s Tristate Care Management Center serves as a dedicated clinical resource and national mentor to providers. You may contact Dr. Ciaverelli with your OBOT treatment-related questions at:
Phone: 410-953-2043
E-mail: RCiaverelli@MagellanHealth.com
For questions related to OBOT contracting and credentialing, contact the network team in your area.
Visit the Substance Abuse and Mental Health Administration (SAMHSA) and National Alliance of Advocates for Buprenorphine Treatment (NAABT) websites for more information on OBOT certification. More details also are included in our OBOT provider sheet and Magellan’s Provider Focus newsletter. In addition, we encourage you to share our OBOT information sheet for members with Magellan members you serve as appropriate.